review article | Q7318358 |
scholarly article | Q13442814 |
P356 | DOI | 10.2307/3346510 |
10.3389/FIMMU.2014.00046 | ||
P888 | JSTOR article ID | 3346510 |
P932 | PMC publication ID | 3920065 |
P698 | PubMed publication ID | 24575095 |
P50 | author | Benjamin D. Singer | Q42382392 |
P2093 | author name string | Landon S King | |
Franco R D'Alessio | |||
P2860 | cites work | Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse | Q24290693 |
Human T regulatory cell therapy: take a billion or so and call me in the morning | Q24656069 | ||
Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 | ||
Gene transfer in humans using a conditionally replicating lentiviral vector | Q24675343 | ||
T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development | Q85350477 | ||
Regulatory T cell-based immunotherapies in experimental autoimmune myasthenia gravis | Q85735927 | ||
Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies | Q27028025 | ||
Control of regulatory T cell development by the transcription factor Foxp3 | Q27860489 | ||
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells | Q27860714 | ||
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases | Q28131652 | ||
Use of epigenetic modification to induce FOXP3 expression in naïve T cells | Q28249415 | ||
Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells | Q28289781 | ||
Multiple immuno-regulatory defects in type-1 diabetes | Q28344695 | ||
Regulatory T cell lineage specification by the forkhead transcription factor foxp3 | Q28510328 | ||
Mechanisms of foxp3+ T regulatory cell-mediated suppression | Q29615842 | ||
The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 | Q29619324 | ||
CTLA-4 control over Foxp3+ regulatory T cell function | Q29619413 | ||
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 | Q29622893 | ||
Failure of CD25+ T cells from lupus-prone mice to suppress lupus glomerulonephritis and sialoadenitis | Q30437306 | ||
Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation | Q33367565 | ||
Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia | Q33629928 | ||
Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset | Q33999106 | ||
Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab | Q34026630 | ||
Specificity requirements for selection and effector functions of CD25+4+ regulatory T cells in anti-myelin basic protein T cell receptor transgenic mice. | Q34032006 | ||
A Disquisition on Suppressor T Cells | Q34051239 | ||
In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells | Q34089068 | ||
Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics | Q34144161 | ||
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation | Q34162461 | ||
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis | Q34311395 | ||
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance | Q34448410 | ||
Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. | Q34529123 | ||
Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells | Q34548321 | ||
Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. | Q34553677 | ||
Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease | Q34556560 | ||
All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation | Q34580976 | ||
CTLA-4: a key regulatory point in the control of autoimmune disease | Q34593985 | ||
Systematic evaluation of 640 FDA drugs for their effect on CD4⁺Foxp3⁺ regulatory T cells using a novel cell-based high throughput screening assay | Q34640983 | ||
CD28 superagonists: what makes the difference in humans? | Q34656318 | ||
Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. | Q37208910 | ||
Itch expression by Treg cells controls Th2 inflammatory responses. | Q37259247 | ||
In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression | Q37273329 | ||
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo | Q37312884 | ||
CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury | Q37363024 | ||
Epigenetic mechanisms of regulation of Foxp3 expression | Q37412329 | ||
Acute graft-versus-host disease: from the bench to the bedside | Q37420496 | ||
Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease | Q37458586 | ||
Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? | Q37493607 | ||
Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. | Q37599553 | ||
Attenuation of donor-reactive T cells allows effective control of allograft rejection using regulatory T cell therapy | Q37603816 | ||
Functional regulatory T cells and allergen immunotherapy. | Q37790956 | ||
Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. | Q37908437 | ||
Tregs: application for solid-organ transplantation | Q37964990 | ||
HDAC inhibitor therapy in autoimmunity and transplantation. | Q37998320 | ||
Regulatory cells in allergen-specific immunotherapy | Q38003474 | ||
Regulatory T-cell therapy for transplantation: how many cells do we need? | Q38025843 | ||
Translating tolerogenic therapies to the clinic - where do we stand? | Q38039091 | ||
Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications. | Q38083439 | ||
Development and maintenance of regulatory T cells | Q38092234 | ||
Induction of transplantation tolerance converts potential effector T cells into graft-protective regulatory T cells. | Q38491611 | ||
CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. | Q39901615 | ||
Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. | Q40003509 | ||
Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production | Q40165347 | ||
A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells | Q40297048 | ||
Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. | Q40565739 | ||
Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. | Q40801370 | ||
Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor | Q41410840 | ||
Transplantation tolerance induced by antigen pretreatment and depleting anti‐CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response | Q41672486 | ||
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. | Q41819445 | ||
CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta | Q42025024 | ||
The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment | Q42593305 | ||
A novel clinically relevant approach to tip the balance toward regulation in stringent transplant model. | Q42827367 | ||
CD154 blockade abrogates allospecific responses and enhances CD4(+) regulatory T-cells in mouse orthotopic lung transplant | Q42907214 | ||
Whole blood flow cytometric measurement of NFATc1 and IL-2 expression to analyze cyclosporine A-mediated effects in T cells | Q43003617 | ||
Low-dose, but not high-dose, cyclosporin A promotes regulatory T-cell induction, expansion, or both. | Q43028008 | ||
Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery | Q43095588 | ||
Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin | Q43266964 | ||
Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease. | Q44114418 | ||
CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation | Q44408941 | ||
Antidepressant drug, desipramine, alleviates allergic rhinitis by regulating Treg and Th17 cells | Q44950102 | ||
Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. | Q45299244 | ||
Foxp3+ regulatory T cells participate in repair of ischemic acute kidney injury. | Q45922599 | ||
In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation. | Q45961710 | ||
Monotherapy rapamycin allows an increase of CD4 CD25 FoxP3 T cells in renal recipients. | Q46005391 | ||
Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. | Q46223676 | ||
CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. | Q46763767 | ||
Deacetylase inhibition promotes the generation and function of regulatory T cells. | Q46961808 | ||
Low-dose cyclosporine A therapy increases the regulatory T cell population in patients with atopic dermatitis. | Q47828390 | ||
Regulatory T cells: recommendations to simplify the nomenclature. | Q48624465 | ||
Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. | Q48788015 | ||
Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. | Q50968365 | ||
Transplantation tolerance: memories that haunt us. | Q51005517 | ||
Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. | Q51765584 | ||
IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. | Q51998742 | ||
Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. | Q53522597 | ||
Glucocorticosteroids modify Langerhans cells to produce TGF-β and expand regulatory T cells. | Q54193154 | ||
Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance | Q56904417 | ||
Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor–based drug regimens | Q60614966 | ||
IL-10 Is Required for Regulatory T Cells to Mediate Tolerance to Alloantigens In Vivo | Q60700622 | ||
Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus | Q61050853 | ||
Mechanism of induction of transplantation tolerance using donor antigen and anti-CD4 monoclonal antibody | Q68188003 | ||
Induction of operational tolerance by random blood transfusion combined with anti-CD4 antibody therapy. A protocol with significant clinical potential | Q72086496 | ||
Modulation of the CD4 molecule is a major event in the induction of transplantation tolerance with anti-CD4 monoclonal antibodies | Q73278713 | ||
Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process | Q75224536 | ||
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells | Q78806915 | ||
In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance | Q79143624 | ||
Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance | Q79468642 | ||
Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation | Q80754264 | ||
Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes | Q80967783 | ||
Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD | Q81014631 | ||
In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice | Q82335403 | ||
Regulatory T cells in cancer | Q84073243 | ||
First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells | Q84135263 | ||
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation | Q34657284 | ||
Control of regulatory T cell lineage commitment and maintenance | Q34658594 | ||
Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates | Q34991139 | ||
Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. | Q34994485 | ||
TNF downmodulates the function of human CD4+CD25hi T-regulatory cells | Q35849817 | ||
The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. | Q35880886 | ||
Initiation of autoimmunity. | Q35931561 | ||
Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction | Q36135190 | ||
Organ transplantation--how much of the promise has been realized? | Q36152685 | ||
Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children | Q36181380 | ||
Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells | Q36228688 | ||
Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice | Q36228938 | ||
CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. | Q36229540 | ||
CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade | Q36369151 | ||
In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. | Q36370315 | ||
Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation | Q36370863 | ||
Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases? | Q36378864 | ||
Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells | Q36384673 | ||
Clinical application of expanded CD4+25+ cells | Q36386636 | ||
In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes | Q36399048 | ||
Regulatory T-cell compartmentalization and trafficking | Q36421407 | ||
Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment | Q36539561 | ||
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity | Q36551599 | ||
Human regulatory T cells and their role in autoimmune disease | Q36563532 | ||
Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells | Q36915913 | ||
CD28 costimulation is essential for human T regulatory expansion and function | Q36916914 | ||
Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis | Q37039571 | ||
Interleukin-2 and regulatory T cells in graft-versus-host disease | Q37055805 | ||
Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation | Q37065897 | ||
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation | Q37088900 | ||
Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity | Q37100901 | ||
Identification of IL-17-producing FOXP3+ regulatory T cells in humans. | Q37122868 | ||
Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells | Q37180691 | ||
P921 | main subject | immunotherapy | Q1427096 |
P304 | page(s) | 46 | |
P577 | publication date | 2014-02-11 | |
P1433 | published in | Frontiers in Immunology | Q27723748 |
P1476 | title | Regulatory T cells as immunotherapy | |
P478 | volume | 5 |
Q39518617 | A Cell Graft or a Drug? Legal and Practical Aspects of Somatic Cells Application in Graft-Versus-Host Disease Experimental Treatment: The Polish Experience |
Q36029353 | A TNFR2-Agonist Facilitates High Purity Expansion of Human Low Purity Treg Cells |
Q26753195 | Adaptive immunity in the liver |
Q39035161 | Adoptive cell transfer in autoimmune hepatitis |
Q35582326 | Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord blood |
Q89121829 | Ag-specific CD4 T cells promote innate immune responses in liver ischemia reperfusion injury |
Q34171339 | Antigen-specific immune reactions to ischemic stroke. |
Q90687084 | Antigen-specific in vitro expansion of factor VIII-specific regulatory T cells induces tolerance in hemophilia A mice |
Q40774020 | Artificial antigen-presenting cells expressing HLA class II molecules as an effective tool for amplifying human specific memory CD4(+) T cells |
Q38758281 | CD11b regulates the Treg/Th17 balance in murine arthritis via IL-6. |
Q92557027 | CD73 Rather Than CD39 Is Mainly Involved in Controlling Purinergic Signaling in Calcified Aortic Valve Disease |
Q38285331 | Cell mediators of autoimmune hepatitis and their therapeutic implications |
Q96303574 | Cell-in-Cell Structures in the Liver: A Tale of Four E's |
Q92840410 | Changes of peripheral blood Vδ1 T cells in patients with atherosclerotic cerebral infarction |
Q85823581 | Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program |
Q42694613 | Clinical Tolerogenic Dendritic Cells: Exploring Therapeutic Impact on Human Autoimmune Disease |
Q92839233 | Clinical significance of Vδ1 T cell detection in sepsis patients |
Q89991575 | CoRESTed development of regulatory T cells |
Q37046528 | Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. |
Q42918630 | Comment on Adamzik et al.: An increased alveolar CD4 + CD25 + Foxp3 + T-regulatory cell ratio in acute respiratory distress syndrome is associated with increased 30-day mortality |
Q58390463 | DNA methylation as a transcriptional regulator of the immune system |
Q89777242 | Delayed Akt suppression in the lipopolysaccharide-induced acute lung injury promotes resolution that is associated with enhanced effector regulatory T cells |
Q36346401 | Differential effect of DJ-1/PARK7 on development of natural and induced regulatory T cells |
Q88072925 | Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension |
Q37200094 | Engagement of SLAMF3 enhances CD4+ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus |
Q49189715 | Enhanced CD25+Foxp3+ regulatory T cell development by amodiaquine through activation of nuclear receptor 4A. |
Q49438074 | Ex Vivo Expanded Human Non-Cytotoxic CD8+CD45RClow/- Tregs Efficiently Delay Skin Graft Rejection and GVHD in Humanized Mice |
Q57284424 | Ex vivo induction of regulatory T cells from conventional CD4 T cells is sensitive to substrate rigidity |
Q39282520 | Expanding Diversity and Common Goal of Regulatory T and B Cells. II: In Allergy, Malignancy, and Transplantation |
Q33878542 | Extracellular adenosine-mediated modulation of regulatory T cells |
Q36118977 | FoxP3 Tregs Response to Sublingual Allergen Specific Immunotherapy in Children Depends on the Manifestation of Allergy |
Q47138817 | Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders |
Q37101147 | Histone/protein deacetylase 3 dictates critical aspects of regulatory T cell development and function |
Q37444403 | Hyperlipidemia Alters Regulatory T Cell Function and Promotes Resistance to Tolerance Induction Through Costimulatory Molecule Blockade |
Q89811064 | Immune correlates of postexposure vaccine protection against Marburg virus |
Q37254938 | Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression |
Q89064904 | Is chronic AhR activation by rapidly metabolized ligands safe for the treatment of immune-mediated diseases? |
Q59136942 | Limited Foxp3 Regulatory T Cells Response During Acute Infection Is Required to Allow the Emergence of Robust Parasite-Specific CD8 T Cell Immunity |
Q91000079 | Loss of Lkb1 impairs Treg function and stability to aggravate graft-versus-host disease after bone marrow transplantation |
Q36307846 | MicroRNA expression profiles in human CD3+ T cells following stimulation with anti-human CD3 antibodies |
Q50223670 | Migratory properties of ex vivo expanded regulatory T cells: Influence of all-trans retinoic acid and rapamycin |
Q35944514 | Missed, Not Missing: Phylogenomic Evidence for the Existence of Avian FoxP3. |
Q40625213 | Mucosal Regulatory T Cells and T Helper 17 Cells in HIV-Associated Immune Activation |
Q58390458 | Multidimensional assessment of alveolar T cells in critically ill patients |
Q51548838 | Notch signalling suppresses regulatory T-cell function in murine experimental autoimmune uveitis. |
Q38827389 | Novel immunotherapies for immune-mediated haemolytic anaemia in dogs and people |
Q37662989 | Old game, new players: Linking classical theories to new trends in transplant immunology |
Q48313873 | Opening the Regulatory T Cell Toolbox |
Q64268733 | Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models? |
Q39210713 | Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis |
Q28081922 | Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells |
Q55064864 | Pathological conversion of regulatory T cells is associated with loss of allotolerance. |
Q38245229 | Redefining Strategies to Introduce Tolerance-Inducing Cellular Therapy in Human beings to Combat Autoimmunity and Transplantation Reactions |
Q55097930 | Regulatory T Lymphocytes in Periodontitis: A Translational View. |
Q35816483 | Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation |
Q30819489 | Regulatory T cell transfer ameliorates lymphedema and promotes lymphatic vessel function |
Q50958283 | Regulatory T-Cell Augmentation or Interleukin-17 Inhibition Prevents Calcineurin Inhibitor-Induced Hypertension in Mice |
Q26798141 | Research Progress on Regulatory T Cells in Acute Kidney Injury |
Q92715753 | Resolution of inflammation in periodontitis: a review |
Q88473015 | S-nitrosoglutathione reductase (GSNOR) inhibitor as an immune modulator in experimental autoimmune encephalomyelitis |
Q39445889 | Sex and Gender Differences in Hypertensive Kidney Injury |
Q58390460 | Systemic lupus erythematosus-associated diffuse alveolar hemorrhage: A case report and review of the literature |
Q55434021 | TNF Receptor Type II as an Emerging Drug Target for the Treatment of Cancer, Autoimmune Diseases, and Graft-Versus-Host Disease: Current Perspectives and In Silico Search for Small Molecule Binders. |
Q90290687 | Targeting Regulatory T Cells by Addressing Tumor Necrosis Factor and Its Receptors in Allogeneic Hematopoietic Cell Transplantation and Cancer |
Q26740179 | Targeting T cells to treat atherosclerosis: odyssey from bench to bedside |
Q28079006 | The CXCL10/CXCR3 Axis and Cardiac Inflammation: Implications for Immunotherapy to Treat Infectious and Noninfectious Diseases of the Heart |
Q43795320 | The adulticide effect of a combination of doxycycline and ivermectin in Dirofilaria immitis-experimentally infected dogs is associated with reduction in local T regulatory cell populations |
Q21131158 | The environment of regulatory T cell biology: cytokines, metabolites, and the microbiome |
Q38510263 | The functional and prognostic implications of regulatory T cells in colorectal carcinoma |
Q61124946 | The lineage stability and suppressive program of regulatory T cells require protein O-GlcNAcylation |
Q64066385 | Transcriptional analysis of Foxp3+ Tregs and functions of two identified molecules during resolution of ALI |
Q41888025 | Treg activation defect in type 1 diabetes: correction with TNFR2 agonism |
Q38787674 | Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease. |
Q58746739 | Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy |
Q37694801 | Utilization of leukapheresis and CD4 positive selection in Treg isolation and the ex-vivo expansion for a clinical application in transplantation and autoimmune disorders |
Q34919712 | mTOR signaling, Tregs and immune modulation |